C
Cellcolabs
S a biotech impact startup on a mission to use advanced cell therapies to disrupt healthcare as we know it through efficient large-scale production of mesenchymal stem cells
About Cellcolabs
Cellcolabs, founded in 2021 and based in Stockholm, Sweden, specializes in the industrial GMP (Good Manufacturing Practice) production of high-quality Mesenchymal Stromal Cells (MSCs). These cells have regenerative, immunomodulatory, and anti-inflammatory properties, which could potentially cure or prevent many chronic diseases. The company aims to make MSCs available at scale to accelerate stem cell research and facilitate the development of future treatments. Cellcolabs does not provide treatments directly but sponsors or partners with clinical studies, offering updates on participation opportunities. The company serves researchers and healthcare providers in the advanced cell therapy market. Its business model revolves around the large-scale production and distribution of MSCs, generating revenue through sales to research institutions and clinical partners. Cellcolabs is committed to transforming healthcare and improving lives through advanced cell therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Solna kommun, Sweden
- Employees
- 78
- Open positions
- 3
- Dealroom signal
- 36.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Nordic Rising Star 2022, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2025 | $12M | $48M | Titan Capital | ↗ |
| EARLY VC✓Equity / VC | Mar 2024 | $8.7M | $35M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Cellcolabs is 3K monthly website visits, up 76.5% over the last three months. Cellcolabs's team declined 7.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
Ash Pournouri
Fredrik Jung-Abbou
Johannes Schildt
Fredrik Hjelm- SCSusanna Campbell
- MBMichaëla Berglund
Jonas Nordlander
Sven Hagströmer
Filip Engelbert- JHJohn Hedberg
Series A1 investor entered at this stage
Titan Capital
Other known investors3 additional known investors
Elias Pour
Norrsken Launcher
Unruly Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cellcolabs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellcolabs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.